Literature DB >> 1818842

Serum adenosine deaminase in pulmonary tuberculosis, malignancy and non-tubercular respiratory diseases.

S K Bansal1, R P Singh, R K Narang, L D Joshi, A Bansal, A K Agrawal.   

Abstract

The study has been conducted to find out the serum ADA levels in 120 patients with various pulmonary diseases which included patients with tubercular pleural effusion (n = 86), lung cancer (n = 10) and patients with non-tubercular pulmonary diseases like pneumonia, etc (n = 24). Twenty healthy individuals served as control subjects. The mean (+/- SD) of ADA activity was 23.38 (4.47), 7.29 (1.08), 12.71 (1.95) and 2.23 (1.00) units/litre in tuberculosis, malignancy, non-tubercular pulmonary diseases and healthy controls respectively with significant difference between each other (P less than 0.001). Patients with tuberculosis (100%) fall in 97% sensitivity range with a lower cut off limit at 17 units/litre ADA activity, while for malignancy and non-tubercular respiratory diseases, the sensitivity was 90% and 83% respectively. Within the sensitivity limits, the serum ADA activity can be used for the differential diagnosis of pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818842

Source DB:  PubMed          Journal:  Indian J Chest Dis Allied Sci        ISSN: 0377-9343


  3 in total

1.  Serum Adenosine Deaminase Levels and Human Papillomavirus as Prognostic and Predictive Factors for Laryngeal and Pharyngeal Carcinomas.

Authors:  C Chandrakiran; Thanu Jogy; Sanjay B Patil
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-04-30

2.  Influence of different sample preparation strategies on the proteomic identification of stress biomarkers in porcine saliva.

Authors:  Ana Gutiérrez; José Joaquín Cerón; Ebrahim Razzazi-Fazeli; Sarah Schlosser; Fernando Tecles
Journal:  BMC Vet Res       Date:  2017-12-04       Impact factor: 2.741

3.  Role of Adenosine Deaminase in Common Chronic ENT Infections.

Authors:  U P Santosh; G S Renukananda; S Abhilash
Journal:  J Clin Diagn Res       Date:  2016-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.